These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24924683)

  • 1. Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms.
    Drug Ther Bull; 2014 Jun; 52(6):69-72. PubMed ID: 24924683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Harry RD; Zakzanis KK
    Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing trends in cognition enhancing drugs in Australia.
    Hollingworth SA; Byrne GJ
    Int Psychogeriatr; 2011 Mar; 23(2):238-45. PubMed ID: 20670461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
    Cappell J; Herrmann N; Cornish S; Lanctôt KL
    CNS Drugs; 2010 Nov; 24(11):909-27. PubMed ID: 20932064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Institute for Clinical Excellence. Alzheimer's drugs given go-ahead.
    Nurs Times; 2001 Jan 25-31; 97(4):7. PubMed ID: 11954136
    [No Abstract]   [Full Text] [Related]  

  • 8. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
    Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of dosing and persistence with anti-dementia medications.
    Brewer L; Bennett K; McGreevy C; Williams D
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1467-75. PubMed ID: 23443628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
    Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
    Psychogeriatrics; 2016 Jan; 16(1):54-61. PubMed ID: 25919986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: Seeing the signs early.
    Leifer BP
    J Am Acad Nurse Pract; 2009 Nov; 21(11):588-95. PubMed ID: 19900220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
    Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
    Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UK government guidance on Alzheimer's drugs postponed.
    O'Neill MF
    Drug Discov Today; 2005 Sep; 10(17):1132. PubMed ID: 16182201
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescription differences of dementia drugs in urban and rural areas in Germany].
    Bohlken J; Selke GW; van den Bussche H
    Psychiatr Prax; 2011 Jul; 38(5):232-6. PubMed ID: 21425036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.